Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
2021 |
| gptkbp:ATCCode |
L01EL04
|
| gptkbp:brand |
gptkb:Exkivity
|
| gptkbp:CASNumber |
gptkb:2389149-74-6
|
| gptkbp:chemicalFormula |
C32H39N9O4
|
| gptkbp:developedBy |
gptkb:Takeda_Pharmaceutical_Company
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mobocertinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
irreversible inhibitor of EGFR
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL4297598
121489515 |
| gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue rash decreased appetite stomatitis paronychia |
| gptkbp:target |
EGFR exon 20 insertion mutations
|
| gptkbp:UNII |
6Q1K1Y1K0I
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|